Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. The company has a product pipeline including a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R), and a complement therapeutics platform that generates fusion proteins intended to downregulate complement activity specifically in disease-affected tissues.